Walleye Capital’s Travere Therapeutics TVTX Stock Holding History

Walleye Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,500	Closed	-$104K	–	5181
2026 Q1	$104K	Sell	3,500 -3,200	-48%	-$95.7K	﹤0.01%	3655
2025 Q4	$256K	Sell	6,700 -2,000	-23%	-$65K	﹤0.01%	3407
2025 Q3	$208K	Buy	+8,700	New	+$164K	﹤0.01%	3294
2024 Q2	–	Sell	-1,400	Closed	-$10.8K	–	6024
2024 Q1	$10.8K	Buy	+1,400	New	+$11.8K	﹤0.01%	5056
2023 Q4	–	Sell	-2,700	Closed	-$24.1K	–	5540
2023 Q3	$24.1K	Buy	+2,700	New	+$38.1K	﹤0.01%	4355

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's TVTX Position: Q2 2026 in Review

Walleye Capital increased its Travere Therapeutics (TVTX) stake by 9,542% in Q2 2026, buying an estimated $1.7M and bringing the position to 38,762 shares worth $2.2M. The position accounts for 0.01% of the portfolio, ranked #1431.

Walleye Capital first reported a position in TVTX in Q3 2019 and has held it in 22 quarters since. The position peaked at $11.3M in Q2 2023. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Walleye Capital held 38,762 shares of Travere Therapeutics worth $2.2M as of Q2 2026.
Walleye Capital bought 38,360 Travere Therapeutics shares in Q2 2026, an estimated $1.7M.
Travere Therapeutics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1431 holding.
Walleye Capital first reported a position in Travere Therapeutics in Q3 2019 and has held it in 22 quarters since.
Walleye Capital's Travere Therapeutics position peaked at $11.3M in Q2 2023.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.